About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death). Recently, however, several new direct-acting antivirals against HCV are available or are in an advanced phase of clinical development.
Beclabuvir for the treatment of hepatitis C / Gentile, Ivan; Zappulo, Emanuela; Buonomo, ANTONIO RICCARDO; Maraolo, ALBERTO ENRICO; Borgia, Guglielmo. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - 24:8(2015), pp. 1111-1121. [10.1517/13543784.2015.1059820]
Beclabuvir for the treatment of hepatitis C
GENTILE, Ivan;ZAPPULO, EMANUELA;BUONOMO, ANTONIO RICCARDO;MARAOLO, ALBERTO ENRICO;BORGIA, GUGLIELMO
2015
Abstract
About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death). Recently, however, several new direct-acting antivirals against HCV are available or are in an advanced phase of clinical development.| File | Dimensione | Formato | |
|---|---|---|---|
|
Scala Gentile.pdf
non disponibili
Descrizione: Articolo principale
Tipologia:
Versione Editoriale (PDF)
Licenza:
Accesso privato/ristretto
Dimensione
5.39 MB
Formato
Adobe PDF
|
5.39 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
